Abstracts tagged "Co-morbidities"

Abstract Number: 381 • 2015 ACR/ARHP Annual Meeting
Associations Between Vitamin D Insufficiency, Osteoporotic Fractures and Comorbidites
Eugenio Chamizo Carmona¹, Juan Jose Aznar Sánchez^1,2, Raul Veroz Gonzalez², Tamara Libertad Rodriguez Araya¹, Piter José Cossio Jimenez² and Sara María Rojas Herrera³, ¹Rheumatology, Hospital de Mérida, Mérida, Spain, ²Hospital de Mérida, Mérida, Spain, ³Rheumatolotgy, Hospital de Mérida, Mérida, Spain
Background/Purpose: Vitamin D deficiency is highly prevalence, especially in adults and elderly population. There is controversy about its relationship with increased cardiovascular risk, osteoporosis and…
Abstract Number: 659 • 2015 ACR/ARHP Annual Meeting
Does the Inclusion of Extra-Articular Manifestations Improve Validity of the Self-Administered Comorbidity Questionnaire Modified for Spondyloarthritis (SpA-SCQ)? Results from ASAS-Comospa
Ivette Essers^1,2, Carmen Stolwijk^1,2, Adrien Etcheto³, Anna Molto⁴, Filip van Den Bosch⁵, Désirée van der Heijde⁶, Robert B.M. Landewé^7,8, Astrid van Tubergen^1,2, Maxime Dougados^4,9 and Annelies Boonen^1,10, ¹School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, Netherlands, ²Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ³Cochin Hospital, Paris Descartes University, Paris, France, ⁴Hopital Cochin, Paris Descartes University, Paris, France, ⁵Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands, Leiden, Netherlands, ⁷Rheumatology, Atrium Medical Center, Heerlen, Netherlands, ⁸Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁹Rheumatology Department, Hôpital Cochin, Paris, France, ¹⁰Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: The self-administered comorbidity questionnaire (SCQ) was developed to understand the impact of 13 common comorbidities on functioning and resource utilisation. In patients with ankylosing…
Abstract Number: 826 • 2015 ACR/ARHP Annual Meeting
Systemic Sclerosis Inpatient Mortality Has Not Improved from 1995-2011. Results from a National Irish Audit of Scleroderma Co-Morbidities.
Len Harty¹, Deirdre Fitzgerald², Michael Henry², John Ryan³ and Sinead Harney³, ¹Cork University Hospital, Cork, Ireland, ²Respiratory, Cork University Hospital, Cork, Ireland, ³Rheumatology, Cork University Hospital, Cork, Ireland
Background/Purpose: Despite the advent of potent immunosuppressive and vasoactive therapies it is not clear that longevity of patients with systemic sclerosis (SSc) has improved. Therefore…
Abstract Number: 912 • 2015 ACR/ARHP Annual Meeting
Secondary Preventive Pharmacotherapy and Longterm Outcomes Following Acute Coronary Events in Patients with Prevalent Rheumatoid Arthritis
Ängla Mantel¹, Marie Holmqvist¹, Tomas Jernberg², Solveig Wållberg-Jonsson³ and Johan Askling^4,5, ¹Dept of Medicine, Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Section of Cardiology, Department of medicine, Karolinska University Hospital, Stockholm, Sweden, ³Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, ⁴Rheumatology Unit, Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden, ⁵Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Suboptimal use of secondary preventive pharmacotherapies after acute coronary syndrome (ACS) in patients with rheumatoid arthritis (RA) has been suggested to contribute to an…
Abstract Number: 1290 • 2015 ACR/ARHP Annual Meeting
Burden of Rheumatoid Arthritis in the US Elderly Population: Comorbidities, Healthcare Resource Utilization, and Cost
Chieh-I Chen¹, Li Wang², Wenhui Wei³, Huseyin Yuce⁴ and Kristine Phillips⁵, ¹Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ²Director, Analytic Research, STATinMED Research, Plano, TX, ³Sanofi-Aventis, Bridgewater, NJ, ⁴New York City College of Technology (CUNY), New York, NJ, ⁵Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease resulting in significant healthcare resource utilization (HRCU) and cost. Data on elderly RA patients are generally…
Abstract Number: 1419 • 2015 ACR/ARHP Annual Meeting
Increasing Comorbidity Is Associated with Worsening Physical Function during Intermediate-Term Follow-up of Primary Total Knee Arthroplasty
Maren Hilton¹, Terence Gioe² and Jasvinder A. Singh³, ¹Arthritis and Rheumatology Consultants, Edina, MN, ²Department of Orthopaedic Surgery, Minneapolis VA Medical Center, Minneapolis, MN, ³University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Total knee arthroplasty (TKA) is associated with significant gains in function and pain improvement. However, decline in function has been noted in patients who…
Abstract Number: 1428 • 2014 ACR/ARHP Annual Meeting
Comparison of Application of the European Society Cardiology, Adult Treatment Panel III, and ACC/AHA Guidelines for Cardiovascular Disease Prevention in a French Cohort of Rheumatoid Arthritis
Martin Soubrier¹, Zuzana Tatar², Maxime Chevreau³, Bruno Pereira⁴, Laure Gossec⁵, P Gaudin⁶ and Maxime Dougados⁷, ¹COMEDRA trial group, Paris, France, ²Centre Jean Perrin, Clermont Ferrand, France, ³Rheumatology, CHU Sud Hospital, Grenoble, France, ⁴Clinical research department, Clermont-Ferrand, France, ⁵Sorbonne Universités, UPMC Univ Paris 06, GRC-08, Institut Pierre Louis d’Epidémiologie et de Santé Publique, paris, France, ⁶CHU Hôpital Sud, Grenoble, France, ⁷RAID working group for EULAR, Zurich, Switzerland
Background/Purpose Cardiovascular risk (CVR) is increased in RA and should be evaluated annually. EULAR recommends using the SCORE equation to calculate risk, after applying a…
Abstract Number: 1313 • 2014 ACR/ARHP Annual Meeting
Comorbidity Patterns in Children with Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus: The Childhood Arthritis and Rheumatology Research Alliance Registry
Marc D. Natter¹, Mei-Sing Ong², Kenneth D. Mandl³, Laura Schanberg⁴, Yukiko Kimura⁵, Norman Ilowite⁶ and the CARRA Registry Investigators, ¹Intelligent Health Labs, Children's Hospital Boston, Boston, MA, ²Australian Institute of Health Innovation, University of New South Wales, Sydney, Australia, ³Intelligent Health Lab, Children's Hospital Boston, Boston, MA, ⁴Duke University, Durham, NC, ⁵Pediatric Rheumatology, Hackensack Univ Medical Ctr, Hackensack, NJ, ⁶Rheumatology, Children's Hospital Montefiore, Bronx, NY
Background/Purpose: Knowledge of co-occurring disease processes (comorbidities) is important for understanding disease pathogenesis, refining disease classifications, developing appropriate screening and prevention strategies, and determining overall…
Abstract Number: 553 • 2014 ACR/ARHP Annual Meeting
Comparison of Baseline Extra-Articular Manifestations, Comorbidities, and Long-Term Safety in Patients Treated with Adalimumab for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Joachim Sieper¹, Désirée van der Heijde², Nupun A. Varothai³ and Jaclyn K. Anderson³, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³AbbVie Inc., North Chicago, IL
Background/Purpose: To compare 1) extra-articular manifestations, 2) baseline comorbidities, and 3) adverse event (AE) rates with long-term adalimumab (ADA) therapy in patients (pts) treated in…
Abstract Number: 422 • 2014 ACR/ARHP Annual Meeting
Correlation of RAPID3, DAS28 and CDAI in Disease Activity and Effects of Education Level and Co-Morbid Diseases on This Assesment in RA
Kubilay Sahin¹, Yasar Karaaslan^2,3, Zeynep Ozbalkan¹, Ahmet Omma¹ and Nesibe Yesil¹, ¹Rheumatology, Ankara Numune Education and Research Hospital, Ankara, Turkey, ²Rheumatology, Hitit University, Corum, Turkey, ³Ankara Numune Training and Research Hospital, Ankara, Turkey
Background/Purpose RAPID3 is an activity index based on only the patient's report in RA. It doesn’t require joint counts and it isn’t time consuming. Therefore…
Abstract Number: 341 • 2014 ACR/ARHP Annual Meeting
Death Receptor 3 Causes Vascular Dysfunction in a Murine Model of Rheumatoid Arthritis
Jessica O Williams¹, Eddie C.Y. Wang², Derek Lang¹ and Anwen S. Williams², ¹Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom, ²Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom
Background/Purpose: Increased cardiovascular (CV) risk is prevalent in several forms of inflammatory arthritides. The mechanisms that regulate CV disease during early inflammatory arthritis are ill-defined.…
Abstract Number: 313 • 2014 ACR/ARHP Annual Meeting
Elevated Cardiovascular Disease Burden and Inflammatory Biomarker Levels in Adults with Juvenile Idiopathic Arthritis
Siobhan Crittenden¹, Elizabeth Coulson^1,2, Vijay Kunadian^3,4,5, Wan-Fai Ng^1,2,6 and H. E. Foster^7,8,9, ¹Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle upon Tyne, United Kingdom, ²Rheumatology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ³Faculty of Medical Sciences, Institute of Cellular Medicine, Newcastle upon Tyne, United Kingdom, ⁴Cardiology, Freeman Hospital, Newcastle upon Tyne, United Kingdom, ⁵Cardiology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ⁶Musculoskeletal Directorate, The Freeman Hospital, Newcastle upon Tyne, United Kingdom, ⁷Paediatric Rheumatology, Newcastle Hospitals NHS Trust and Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom, ⁸Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle Upon Tyne, United Kingdom, ⁹Paediatric Rheumatology, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom
Background/Purpose: Rheumatoid Arthritis (RA) is associated with a 50 % greater cardiovascular mortality rate than the general population, attributable to the increased prevalence of traditional…
Abstract Number: 99 • 2014 ACR/ARHP Annual Meeting
Impact of Comorbidities on Health Resource Utilization in Patients with Spa
Mariano Andrés¹, Francisca Sivera², Sabina Pérez-Vicente³, Loreto Carmona⁴ and Paloma Vela^1,5, ¹Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain, ²Sección de Reumatología, Hospital General Universitario de Elda, Alicante, Spain, ³Unidad de Investigación de la Sociedad Española de Reumatología, Madrid, Spain, ⁴Instituto de Salud Musculoesquelética, Madrid, Spain, ⁵Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain
Background/Purpose: Similar to other rheumatic disorders, patients with spondyloarthritis (SpA) show an increased prevalence of comorbidities compared to the general population [1]. Comorbidities influence management,…
Abstract Number: 70 • 2014 ACR/ARHP Annual Meeting
The Odds of Work Disability, Unemployment and Depending on Living Allowances Are More Influenced By the Number of Morbidities Than By the Presence of a Musculoskeletal Disease
Antje van der Zee-Neuen¹, Polina Putrik², Sofia Ramiro³, Andras Keszei⁴, Rob de Bie⁵, Astrid M. Chorus⁶ and Annelies Boonen⁷, ¹Internal Medicine, Rheumatology, Maastricht University, Maastricht, Netherlands, ²Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ³Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam & Hospital Garcia de Orta, Almada, Portugal, Amsterdam, Netherlands, ⁴Medical Informatics, RWTH Aachen University, Aachen, Germany, ⁵Epidemiology, Maastricht University, Maastricht, Netherlands, ⁶Netherlands Organization for Applied Scientific Research, Leiden, Netherlands, ⁷Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: The prevalence of multimorbidity (≥ 2 chronic morbidities in 1 person), is increasingly common also in patients at working age. Musculoskeletal diseases (MSKD) are…
Abstract Number: 43 • 2014 ACR/ARHP Annual Meeting
Deaths Associated with Ankylosing Spondylitis in France from 1969 to 2009
Clement Prati¹, Daniel Wendling² and Xavier Guillot³, ¹Rhumatologie, Hopital Jean Minjoz, Besancon, France, ²Service de Rhumatologie, CHU J Minjoz, Besancon, France, ³rheumatology, Besançon, France
Background/Purpose Ankylosing spondylitis (AS) is a chronic inflammatory joint disease that can lead to chronic pain in the axial and peripheral joints and to functional…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].